Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Yester F., Feitsma, Eline A., Boersma, Hendrikus H., Alleva, David G., Lancaster, Thomas M., Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Delpero, Andrea R., Scully, Melanie M., Ragupathy, Ramya, Kotha, Sravya, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Ronca, Shannon E., Green, Freedom M., Aminetzah, Ari, Sollie, Frans, Kruijff, Schelto, Brom, Maarten, van Dam, Gooitzen M., Zion, Todd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802018/
https://www.ncbi.nlm.nih.gov/pubmed/35115195
http://dx.doi.org/10.1016/j.vaccine.2022.01.043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802018/
https://www.ncbi.nlm.nih.gov/pubmed/35115195
http://dx.doi.org/10.1016/j.vaccine.2022.01.043

Ejemplares similares